By leveraging RNS-associated biomarkers to guide personalized interventions (e.g., iNOS inhibitors for high-RNS tumors, NO donors for low-RNS tumors), RNS-targeted strategies can address the heterogeneity of cancer and improve patient outcomes. This evidence concerns the gene NOS2 and cancer.